Opendata, web and dolomites

TherVacB SIGNED

THERVACB: A THERAPEUTIC VACCINE TO CURE HEPATITIS B

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TherVacB project word cloud

Explore the words cloud of the TherVacB project. It provides you a very rough idea of what is the project "TherVacB" about.

host    occurrence    form    translational    infectious    cells    recruitment    quantify    breaking    human    tackle    therapeutic    excellent    hbv    hepatitis    immunity    infection    patient    ib    biomarkers    virus    efficacy    found    stigmatize    realized    lacks    spontaneous    burden    secured    predict    models    boost    thervacb    components    diagnostic    of    record    safety    clinical    activate    options    protected    antibodies    95    polymerase    particulate    center    proof    worldwide    gmp    treatment    preclinical    induce    scheme    diseases    boosted    innovative    inducing    media    chronic    care    immune    vaccination    therapy    track    expressing    perform    cell    approved    vaccine    injections    heterologous    capacity    adjuvanted    iia    protein    virology    cure    monitoring    lacking    interaction    neutralizing    tolerance    tanzania    resolution    proving    prime    clinically    vector    africa    experts    arm    ethical    carries    gt    patients    registry    ip    social    trial    first    local    antigens    mva    proven    tend    interdisciplinary    empirical    obtain    core    prepare    immunology    resistance    jointly   

Project "TherVacB" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH 

Organization address
address: INGOLSTADTER LANDSTRASSE 1
city: NEUHERBERG
postcode: 85764
website: www.helmholtz-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 10˙425˙686 €
 EC max contribution 10˙425˙686 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) coordinator 4˙049˙761.00
2    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 1˙394˙787.00
3    CTC NORTH GMBH & CO KG DE (HAMBURG) participant 1˙113˙125.00
4    AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA IT (PARMA) participant 714˙893.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 675˙380.00
6    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 536˙023.00
7    NATIONAL INSTITUTE FOR MEDICAL RESEARCH TZ (DAR ES SALAAM) participant 489˙287.00
8    ARTTIC FR (PARIS) participant 272˙746.00
9    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 209˙350.00
10    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 191˙556.00
11    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 153˙750.00
12    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) participant 146˙500.00
13    UNIVERSITAET LEIPZIG DE (LEIPZIG) participant 142˙900.00
14    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 131˙125.00
15    BARTS AND THE LONDON NHS TRUST UK (LONDON) participant 104˙500.00
16    ROYAL FREE LONDON NHS FOUNDATION TRUST UK (LONDON) participant 100˙000.00

Map

 Project objective

Experts in virology, immunology and clinical hepatitis B patient care with an excellent research and translational track record in hepatitis B virus (HBV)-host interaction form the interdisciplinary TherVacB consortium. They jointly tackle the major challenges in HBV therapy – the virus’s resistance to cure. TherVacB aims at breaking immune tolerance in chronic HBV infection and achieving HBV cure. Occurrence of neutralizing antibodies and HBV-specific T cell responses characterize spontaneous resolution of HBV infection that are lacking in chronic infection. We will use our IP-protected heterologous prime-boost therapeutic vaccination scheme with proven efficacy in preclinical models of hepatitis B to target and activate B and T cell responses. Two protein prime injections with clinically approved, adjuvanted particulate HBV S and core protein antigens shall induce neutralizing antibodies and prime T cells that are boosted with an MVA vector expressing HBV core, S, L and polymerase antigens covering >95% of HBV found worldwide. Having secured significant funding and partnerships to obtain GMP-produced vaccine components and to prepare a first-in-human application, TherVacB aims at a clinical proof-of-concept of the therapeutic hepatitis B vaccine in patients with chronic hepatitis B. The consortium will establish a patient registry and perform a multi-center phase Ib/IIa clinical trial that aims at proving safety of the therapeutic vaccine and inducing immune control of chronic HBV infection. One study arm will be realized in Tanzania to build up local capacity, because Africa carries a large burden of HBV infection but lacks diagnostic and therapeutic options. An innovative immune monitoring will quantify HBV-specific immunity and define novel biomarkers to predict treatment response. Finally an ethical and an empirical study will evaluate the recruitment of patients by social media which is very effective for infectious diseases that tend to stigmatize patients

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERVACB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERVACB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More